Chien-Yu Cheng to Humans
This is a "connection" page, showing publications Chien-Yu Cheng has written about Humans.
Connection Strength
0.051
-
Clinical validation of an automated reverse transcription-insulated isothermal PCR assay for the detection of severe acute respiratory syndrome coronavirus 2. J Microbiol Immunol Infect. 2021 Jun; 54(3):522-526.
Score: 0.007
-
Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan. J Microbiol Immunol Infect. 2020 Jun; 53(3):488-492.
Score: 0.007
-
Clinical presentations, laboratory results and outcomes of patients with Kikuchi's disease: emphasis on the association between recurrent Kikuchi's disease and autoimmune diseases. J Microbiol Immunol Infect. 2010 Oct; 43(5):366-71.
Score: 0.004
-
Nasal high flow cannula maybe prioritized in treating patients suffering from COVID-19? J Formos Med Assoc. 2021 11; 120(11):2048-2049.
Score: 0.002
-
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021 04 15; 12(1):2349.
Score: 0.002
-
Breadth and function of antibody response to acute SARS-CoV-2 infection in humans. PLoS Pathog. 2021 02; 17(2):e1009352.
Score: 0.002
-
Multicenter evaluation of four immunoassays for the performance of early diagnosis of COVID-19 and assessment of antibody responses of patients with pneumonia in Taiwan. J Microbiol Immunol Infect. 2021 Oct; 54(5):816-829.
Score: 0.002
-
A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). PLoS One. 2020; 15(12):e0242763.
Score: 0.002
-
Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan. Emerg Microbes Infect. 2020 Dec; 9(1):2157-2168.
Score: 0.002
-
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nat Struct Mol Biol. 2020 10; 27(10):950-958.
Score: 0.002
-
Rapid establishment of a COVID-19 biobank in NHRI by National Biobank Consortium of Taiwan. Biomed J. 2020 08; 43(4):314-317.
Score: 0.002
-
A case of transient existence of SARS-CoV-2 RNA in the respiratory tract with the absence of anti-SARS-CoV-2 antibody response. Int J Infect Dis. 2020 Jul; 96:464-466.
Score: 0.002
-
Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients. J Infect. 2020 08; 81(2):e55-e58.
Score: 0.002
-
Letter to the Editor: Update on the followed-up CT exam of the first CoVID-19 pneumonia in Taiwan. J Formos Med Assoc. 2020 06; 119(6):1121-1122.
Score: 0.002
-
Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: systematic review and meta-analysis of randomised controlled trials. BMJ. 2019 Jul 08; 366:l4179.
Score: 0.002
-
Circumcision to prevent HIV and other sexually transmitted infections in men who have sex with men: a systematic review and meta-analysis of global data. Lancet Glob Health. 2019 04; 7(4):e436-e447.
Score: 0.002
-
Less Severe but Prolonged Course of Acute Hepatitis A in Human Immunodeficiency Virus (HIV)-Infected Patients Compared With HIV-Uninfected Patients During an Outbreak: A Multicenter Observational Study. Clin Infect Dis. 2018 10 30; 67(10):1595-1602.
Score: 0.002
-
Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan. PLoS One. 2018; 13(3):e0194149.
Score: 0.002
-
Multiple types of human papillomavirus infection and anal precancerous lesions in HIV-infected men in Taiwan: a cross-sectional study. BMJ Open. 2018 01 27; 8(1):e019894.
Score: 0.002
-
Evolution of hepatitis A virus seroprevalence among HIV-positive adults in Taiwan. PLoS One. 2017; 12(10):e0186338.
Score: 0.001
-
Trends and outcomes of late initiation of combination antiretroviral therapy driven by late presentation among HIV-positive Taiwanese patients in the era of treatment scale-up. PLoS One. 2017; 12(6):e0179870.
Score: 0.001
-
Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan. PLoS One. 2017; 12(2):e0171596.
Score: 0.001
-
Skin rash related to once-daily boosted darunavir-containing antiretroviral therapy in HIV-infected Taiwanese: incidence and associated factor. J Infect Chemother. 2014 Aug; 20(8):465-70.
Score: 0.001